Melissa

New York-based events and TV producer, nonprofit co-founder, mother of three, and wife Melissa Gerstein spent a lot of time pushing through before discovering Tosymra®.

“I just felt like ‘When is this going to end? When can I get up? When can I turn the lights on? When can I go outside and hit the busy streets of NYC?’”

Read story

Susan

Susan is a busy woman on the go. She doesn’t have time to miss out on time with her family because of migraine pain.

“Because of Tosymra®, I feel prepared for my migraines. I feel prepared to face the world. I’ve got what I need.”

Read story

Joy

For Joy, like for so many others, the symptoms that accompany the pain are just as devastating as the migraine itself. She takes comfort in the resource she’s found in Tosymra®.

“I noticed a big difference really. Not only did I get fast relief from [Tosymra®], but for me it lasted!! That was my biggest ‘Oh my gosh! It is better for me’ moment.”

Read story

Stories are from real patients taking Tosymra® who have been compensated for sharing their story.

Tosymra® is a prescription medicine used to treat acute migraine with or without aura in adults.

Tosymra® is not used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines. Tosymra® is not used to treat cluster headaches.

Tosymra® is not used to prevent or decrease the number of migraines you have. It is not known if Tosymra® is safe and effective in children under 18 years of age.

Share your story

Share your story to help bring awareness to others who suffer from migraine.

Please contact us if you are:
– Currently treating your migraines with Tosymra®.
– At least 18 years of age.
– Live in the United States.

Email us

References:

  1. Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2021.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
  3. Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.